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Abstract
Introduction: The purpose of this study was to compare the diagnostic accuracy of dual-energy contrast-
enhanced digital mammography (CEDM) as an adjunct to mammography (MX) ± ultrasonography (US) with the
diagnostic accuracy of MX ± US alone.
Methods: One hundred ten consenting women with 148 breast lesions (84 malignant, 64 benign) underwent two-
view dual-energy CEDM in addition to MX and US using a specially modified digital mammography system
(Senographe DS, GE Healthcare). Reference standard was histology for 138 lesions and follow-up for 12 lesions. Six
radiologists from 4 institutions interpreted the images using high-resolution softcopy workstations. Confidence of
presence (5-point scale), probability of cancer (7-point scale), and BI-RADS scores were evaluated for each finding.
Sensitivity, specificity and ROC curve areas were estimated for each reader and overall. Visibility of findings on MX ±
CEDM and MX ± US was evaluated with a Likert scale.
Results: The average per-lesion sensitivity across all readers was significantly higher for MX ± US ± CEDM than for
MX ± US (0.78 vs. 0.71 using BIRADS, p = 0.006). All readers improved their clinical performance and the average
area under the ROC curve was significantly superior for MX ± US ± CEDM than for MX ± US ((0.87 vs 0.83, p =
0.045). Finding visibility was similar or better on MX ± CEDM than MX ± US in 80% of cases.
Conclusions: Dual-energy contrast-enhanced digital mammography as an adjunct to MX ± US improves
diagnostic accuracy compared to MX ± US alone. Addition of iodinated contrast agent to MX facilitates the
visualization of breast lesions.
Introduction
Though widely established as the only screening imaging
modality that can reduce breast cancer mortality, mam-
mography (MX) has some limitations, such as lesions
masked by normal fibroglandular tissue, lesions seen on
only one view, and subtle architectural distortions [1,2].
Partly because of these limitations, MX misses about 20%
of invasive breast cancers [3,4]. Full-field digital mammo-
graphy (FFDM) enables high-quality breast images with
higher-contrast resolution, improved dynamic range, and
rapid processing of data and images compared with screen
film MX. FFDM has been shown to provide increased
accuracy in screening pre- or peri-menopausal women,
women younger than 50, and women with dense breasts
[5]. Moreover, FFDM offers the possibility of developing
new and advanced applications for breast imaging. Con-
trast-enhanced digital mammography (CEDM) with injec-
tion of an iodinated contrast agent is one of them.
Contrast agent has been used for many years in both
computed tomography (CT) and magnetic resonance
imaging (MRI) examinations to explore angiogenesis in
breast carcinoma by tracking the uptake and washout of
contrast agent in tissues. Iodinated contrast-enhanced
conventional CT was shown to be useful for detecting
breast carcinoma [6]. However, conventional CT results
in a high-radiation dose to the breast and chest wall.
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Recent studies on dedicated breast CT with radiation
doses similar to or slightly higher than those of two-view
MX have shown that malignant lesions were significantly
more conspicuous at contrast-enhanced breast CT than
at MX and have suggested the potential usefulness of
quantitating enhancement of breast lesions in predicting
malignancy [6,7]. Breast MRI using gadolinium-based
contrast agents is currently considered the most sensitive
imaging technique for the detection of breast carcinoma,
and multiple indications have been established for breast
MRI [8]. However, breast MRI has a variable specificity
and positive predictive value and is more time-consum-
ing and approximately 10 times more expensive than MX
[9,10].
Investigational clinical results on CEDM have been pub-
lished during the last few years, suggesting that the techni-
que may be a useful adjunct to MX with lesion contrast
uptake information [11-14]. Two CEDM examination
techniques have been investigated: temporal subtraction
and dual-energy. The study by Lewin and colleagues [11]
is the only published preliminary clinical experience using
dual-energy CEDM. The authors showed the technical
and clinical feasibility of this technique and reported a
sensitivity of 92% and a specificity of 83% for the detection
of breast carcinoma [11]. This study was limited, however,
in that the x-ray beam was not optimized for dual-energy
acquisition and the number of subjects was small. More-
over, no comparison was made between CEDM and MX
interpreted in association with ultrasonography (US), a
routine of care in the diagnostic setting.
Purpose
The objective of the multireader study presented in this
article was to quantify the diagnostic accuracy of dual-
energy CEDM as an adjunct to MX ± US, with that of MX
± US, in a larger patient cohort. We also evaluated lesion
visibility with MX ± CEDM compared with MX ± US.
Materials and methods
Patients
From March 2007 to March 2008, 122 consecutive
patients provided written informed consent and partici-
pated in the study. The study was approved by the ethics
committee (Comité de protection des personnes, Ile de
France) and the institutional review board. Inclusion cri-
teria were recalls from screening with unresolved findings
after MX and ultrasound. Exclusion criteria were isolated
clusters of microcalcifications, pregnancy or possible preg-
nancy, or a history of allergic reaction to an iodinated con-
trast agent. Data from two patients were excluded from
analysis because these patients were later determined to
be ineligible (one patient had breast implants and one
patient was undergoing chemotherapy at the time of ima-
ging). Data from the first 10 patients were used for
training cases and were also excluded from the analysis.
The remaining 110 patients, who had a mean age ± stan-
dard deviation (SD) of 57 ± 11.8 years, formed the study
group. Reference standard for each lesion was obtained
through surgery (82 lesions; 55%), core biopsy (42 lesions;
28%), fine-needle aspiration (11 lesions; 7%), or follow-up
of at least 3 years, median 47 months (12 findings; 8%, all
benign); one lesion with unknown reference standard pro-
cedure was classified as benign (Table 1). The same image
data set used in this study was used in an investigational
single-reader study that evaluated the clinical performance
of CEDM in comparison with MX and MX ± US [15].
This paper reports the results of a multireader study evalu-
ating the diagnostic value of CEDM as an adjunct to MX ±
US (CEDM ± MX ± US versus MX ± US).
Table 1 Characteristics of study lesions
Benign (n =
64)
Malignant (n =
84)
Total (n =
148)
Palpable
Yes 14 (23) 28 (34) 42 (29)
No 48 (77) 55 (66) 103 (71)
Laterality
Right 41 (64) 48 (57) 89 (60)
Left 23 (36) 36 (43) 59 (40)
Type of findings on
MX
Mass 27 (42) 46 (55) 73 (49)
Asymmetry 9 (14) 4 (5) 13 (9)
Distortion 3 (5) 3 (4) 6 (4)
Intramammary
node
1 (2) 0 (0) 1 (1)
Mass ± calcs 6 (9) 20 (24) 26 (18)
Asymmetry ±
calcs
1 (2) 0 (0) 1 (1)
Calcs 3 (5) 8 (10) 11 (7)
Unknown 14 (22) 3 (4) 17 (11)
Procedure
Surgery 24 (38) 58 (69) 82 (55)
Core biopsy 19 (30) 23 (27) 42 (28)
FNAB 8 (12) 3 (4) 11 (7)
Follow-up 13 (20) 0 (0) 13 (9)
Histological grade
G1 26 (31)
G2 33 (39)
G3 12 (14)
Unknown 13 (15)
US images available
Yes 51 (80) 73 (87) 124 (84)
No 13 (20) 11 (13) 24 (16)
Values are presented as number and percentage unless otherwise noted.
calcs, calcifications; FNAB, fine-needle aspiration biopsy; MX, mammography;
US, ultrasonography.
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Dual-energy CEDM examinations
All CEDM examinations were performed with an experi-
mental device that was developed by GE Healthcare
(Chalfont St. Giles, UK) and that allowed dual-energy
CEDM acquisitions. The system used was a commercially
available FFDM system (Senographe DS; GE Healthcare)
that was modified to shape the x-ray spectrum specifi-
cally for CEDM [16]. Dual-energy CEDM was performed
by acquiring a pair of low- and high-energy images in
quick succession during a single breast compression.
Low-energy images were acquired with molybdenum
(Mo) or rhodium (Rh) target and Mo or Rh filter at peak
kilovoltage (kVp) values ranging from 26 to 31, ensuring
that the entire x-ray spectrum was below the k-edge of
iodine (33.2 keV). High-energy images were acquired
with Mo target and a double-layer filter (0.3 mm copper
± 0.3 mm aluminum) at 45 to 49 kVp, ensuring that the
average energy of the x-ray spectrum was just above the
k-edge of iodine. Exposures were performed by using an
anti-scatter grid. Iodine-enhanced images were generated
from the low- and high-energy images. They display the
regions of iodine contrast uptake while canceling non-
enhancing anatomic noise in the images. The appropriate
combination of low- and high-energy images is deter-
mined on the basis of simulations of low- and high-
energy signal levels and depends on low- and high-energy
spectra as well as the compressed breast thickness [17].
A catheter was inserted into the antecubital vein of the
arm contralateral to the breast of concern. A one-shot
intravenous injection of 1.5 mL/body weight of non-ionic
contrast media (Xenetix 300; Guerbet, Villepinte, France)
was then performed by the radiographer in charge by
using a power injector (Medrad, Pittsburgh, PA, USA).
The injection rate was 3 mL/s. Two minutes after the
initiation of contrast administration, the breast was com-
pressed in the mediolateral oblique (MLO) view, and a
low- and high-energy pair of images was acquired within
20 seconds of one another. The breast was then com-
pressed in the craniocaudal (CC) position, and a new low-
and high-energy pair of exposures was acquired 4 minutes
after the initiation of contrast administration. A combina-
tion of low- and high-energy images was performed
through appropriate image processing to generate two
iodine-enhanced images with contrast uptake information,
one in MLO and the other in CC projection.
The total x-ray dose per view delivered to the patient
from the pair of low- and high-energy images was between
0.7 and 3.6 mGy, depending on breast thickness (30 to 80
mm) and tissue composition (0% to 100% glandular tissue)
(Figure 1). A model of the imaging chain was used to esti-
mate the average glandular dose. It is based on the brems-
strahlung spectrum model by Birch and Marshall [18], and
characteristic rays were added from tabulated data. Scat-
tered radiation is included in the model: it is expressed as
a fraction of the primary radiation, whose value depends
on the breast thickness and has been determined experi-
mentally. Estimated values of the dose for standard MX
spectra were in good agreement with published data from
Figure 1 Estimated average glandular dose per view (in milligrays) for contrast-enhanced digital mammography (CEDM) in
comparison with mammography (MX) for 50% glandular breast. The solid line is the dose for one CEDM view, and the dotted line is for
one MX view.
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Wu and colleagues [19], and the mean difference was 3%.
For the high-energy spectra, the comparison of average
glandular dose for an Mo/Cu 49 kVp spectrum gave
approximately 5% relative difference compared with
Boone’s results [20]. The dose estimated from low- and
high-energy views combined is about 1.2 times the dose
delivered in standard single-view digital MX.
Image analysis
Seven experienced breast radiologists from five institu-
tions read MX, US, and CEDM images independently
and were blinded to each patient’s cancer status. MX and
US examinations used for the reading session were those
performed by the referring physician in charge as part of
standard of care before inclusion in the study. Readings
were performed on individual workstations, loaded with
all cases, and calibrated within controlled ambient light-
ing conditions. Prior to study readings, a training session
was run by a radiologist who participated in case collec-
tion. Ten training cases were provided to familiarize radi-
ologists with CEDM and the reading protocol. Iodine-
enhanced CEDM images were reviewed by using reading
criteria based on contrast enhancement intensity and
Table 2 Areas under proper binormal receiver operating
characteristic curves constructed from responses on the
BI-RADS scale
Reader MX ± US MX ± US ± CEDM Increase in Az
1 0.835 ± 0.047 0.872 ± 0.041 0.037 ± 0.026
2 0.907 ± 0.042 0.916 ± 0.030 0.009 ± 0.036
3 0.843 ± 0.042 0.851 ± 0.044 0.009 ± 0.031
4 0.809 ± 0.047 0.849 ± 0.040 0.041 ± 0.026
5 0.791 ± 0.050 0.844 ± 0.040 0.053 ± 0.041
6 0.780 ± 0.049 0.891 ± 0.032 0.111 ± 0.033 (P = 0.001)
Overall 0.827 ± 0.036 0.871 ± 0.027 0.043 ± 0.019
95% CI 0.756 to 0.899 0.817 to 0.92 0.001 to 0.085 (P = 0.045)
Az, area under receiver operating characteristic curve estimated by using
proper binormal model; BI-RADS, Breast Imaging, Reporting and Data System;
CEDM, contrast-enhanced digital mammography; CI, confidence interval,
inference used MRMC methods; MX, mammography; US, ultrasonography.
Figure 2 Estimated proper binormal receiver operating characteristic curves from BI-RADS assessments for the six readers. The red line
is MX ± US ± CEDM, and the blue line is MX ± US. BI-RADS, Breast Imaging, Reporting and Data System; CEDM, contrast-enhanced digital
mammography; MX, mammography; US, ultrasonography.
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morphology similar to those described in the Breast Ima-
ging, Reporting and Data System (BI-RADS) MRI lexicon
developed by the American College of Radiology [8]. For
MX examination only, the two CC and MLO images
were reviewed without any additional views. For US
examinations only, still images (screen saved by the refer-
ring radiologist who performed the free-hand US exami-
nation) were reviewed. Training cases, as well as readings
by the radiologist who was from the collecting institution
and who performed the single-reader study previously
published, were excluded from the analysis. Since the
goal of our study was to evaluate the clinical benefit of
CEDM as an adjunct to MX ± US, each radiologist inter-
preted each case independently and in two sequential
steps during the same reading session: (a) MX ± US and
(b) MX ± US ± CEDM. At each step, readers were
required to assess the case, localize the findings, give BI-
RADS scores, then complete and save an electronic data
form. To conclude the assessment of a case, the truth
(location and nature of known lesions) was communi-
cated after electronic data submission and each reader
was asked to rate relative feature visibility with MX ±
CEDM and MX ± US displayed side by side.
Data forms were completed with the following informa-
tion: patient identification, breast density on MX (BI-
RADS scores of 1 to 4), location of each finding (limited
to the three most suspicious per breast), type of each find-
ing (asymmetry, calcification, mass/density, calcification ±
mass, and scar/distortion), confidence in presence of each
finding (5-step scale in which 1 = very low and 5 = very
high), probability of malignancy for each finding (7-step
scale in which 1 = extremely low and 7 = extremely high),
BI-RADS classification (1 to 5, BI-RADS scores of 0 and 6
were not allowed), and side-by-side feature visibility rating
with MX ± CEDM versus MX ± US (5-step Likert scale,
Table 3 Sensitivity (per-patient) and specificity using BI-
RADS score of at least 4 to define a positive test
Reader MX ± US MX ± US ± CEDM Difference P value
Sensitivity
1 0.875 ± 0.042 0.922 ± 0.034 0.047 0.25
2 0.953 ± 0.027 0.938 ± 0.030 -0.016 1.00
3 0.922 ± 0.034 0.938 ± 0.030 0.016 1.00
4 0.969 ± 0.022 0.953 ± 0.027 -0.016 1.00
5 0.938 ± 0.030 0.859 ± 0.044 -0.078 0.07
6 0.875 ± 0.042 0.906 ± 0.037 0.031 0.68
Overall 0.922 ± 0.028 0.919 ± 0.031 -0.003 ± 0.022 0.91
95% CI 0.866 to 0.977 0.858 to 0.981 -0.052 to 0.047
Specificity
1 0.565 ± 0.074 0.457 ± 0.074 -0.109 0.18
2 0.478 ± 0.074 0.587 ± 0.073 0.109 0.23
3 0.413 ± 0.073 0.457 ± 0.074 0.043 0.68
4 0.174 ± 0.057 0.239 ± 0.064 0.065 0.37
5 0.326 ± 0.07 0.413 ± 0.073 0.087 0.34
6 0.565 ± 0.074 0.609 ± 0.073 0.043 0.77
Overall 0.42 ± 0.073 0.46 ± 0.071 0.040 0.336
95% CI 0.262 to 0.578 0.308 to 0.613 -0.046 to 0.126
Values are presented as estimate ± standard error unless otherwise indicated.
BI-RADS, Breast Imaging, Reporting and Data System; CEDM, contrast-
enhanced digital mammography; CI, confidence interval; MX, mammography;
US, ultrasonography.
Figure 3 Invasive lobular carcinoma in a 67-year-old woman
with left nipple stiffness and retraction. The right craniocaudal
mammogram is normal.
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-2 = MX ± US definitely superior and ± 2 = MX ± CEDM
definitely superior).
Statistical analysis methods
The primary end point was area under the receiver
operating characteristic (ROC) curve. A case was
classified as negative if the patient had no malignant
breast lesions by the reference standard or as positive if
she had at least one proven malignant breast lesion. For
each reader in each reading paradigm, we obtained the
per-patient BI-RADS score as the maximum of the 5-
point BI-RADS scores assigned by the reader to all find-
ings in that patient; the per-patient 7-point probability
Figure 4 Invasive lobular carcinoma in a 67-year-old woman
with left nipple stiffness and retraction. The left craniocaudal
mammogram shows a left cutaneous nipple and areolar thickness
with no obvious lesion in the breast parenchyma.
Figure 5 Invasive lobular carcinoma in a 67-year-old woman
with left nipple stiffness and retraction. The right mediolateral
oblique mammogram is normal.
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of cancer score was obtained similarly. Smooth ROC
curves were estimated on the basis of each of the BI-
RADS and probability of cancer scales by using a proper
binormal model [21,22] in DBM MRMC software from
the University of Chicago [23]. Per-patient analysis of
accuracy included the secondary end points of sensitivity
and specificity, and a positive test was defined as a score
of 4 or higher for both BI-RADS and probability of can-
cer scales. The achieved statistical power of ROC
MRMC was greater than 80%.
Additional secondary end points were lesion-based sen-
sitivity and false-positive marks per negative case. A
reader was determined to have successfully located a real
lesion (malignant or benign) if he or she marked a find-
ing in a quadrant matching the true location of the lesion
and described a finding type consistent with the true
finding type. When finding type could not be determined
for truth, any finding type in the appropriate location was
considered a match. When neither finding type nor loca-
tion was available from truth, any marked finding was
considered to match the real lesion. A reader’s mark was
considered a true positive if it matched a malignant
lesion and the reader’s score for that finding was 4 or
higher for each of the BI-RADS and probability of cancer
scales. A reader’s mark was considered a false positive if
it matched a benign lesion or did not match a real lesion
and if the reader’s score for that finding was 4 or higher.
For each reader in each reading paradigm, sensitivity to
malignant lesions was computed as the number of true-
positive marks divided by the number of malignant
lesions. This result was complemented by computing the
average number of false-positive marks per case in cases
with no malignant lesions.
Figure 6 Invasive lobular carcinoma in a 67-year-old woman
with left nipple stiffness and retraction. The left mediolateral
oblique mammogram shows a left cutaneous nipple and areolar
thickness with no obvious lesion in the breast parenchyma.
Figure 7 Invasive lobular carcinoma in a 67-year-old woman
with left nipple stiffness and retraction. The iodine-enhanced,
contrast-enhanced digital mammography, craniocaudal image
clearly depicts non-mass regional enhancement in the inner
quadrant.
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Feature visibility ratings were tabulated for each reader
and summarized across all readers. A confidence inter-
val (CI) for the proportion of MX ± CEDM ratings as
‘similar’, ‘slightly better’, or ‘better’ was obtained by
using the model of Obuchowski and Rockette (1995)
[24], considering the side-by-side comparison to be a
single test condition.
Multireader, multicase ROC curve analysis used the
method of Dorfman, Berbaum, and Metz (1992) [25] as
implemented in DBM MRMC version 2.2 [26-31].
Within-reader comparisons of sensitivity and specificity
used McNemar’s chi-squared test, and comparison of
false-positive marks per case used the Wilcoxon signed
rank test. Multireader, multicase analysis of per-patient
sensitivity and specificity and of per-lesion sensitivity
and false-positive marks per case used the models of
Obuchowski and Rockette (1995) [24] and was imple-
mented in Splus (version 6.2 for Windows, Professional
Edition). Statistical tests were performed at a signifi-
cance level alpha of 0.05. Two-sided 95% CIs were used
to quantify uncertainty.
Results
The 110 eligible patients presented with a total of 148
breast lesions: 82 patients (75%) had a single breast
lesion, 18 (16%) had two, and 10 (9%) had three. Eighty-
four lesions were malignant and 64 were benign. Most
lesions (103, or 70%) were non-palpable. The mean his-
tological size of lesions was 15.9 mm (SD = 10.9 mm, n
= 70). Lesions generally appeared on MX as masses or
similar (93, or 63%: 73 masses, 13 asymmetries, six dis-
tortions, and one intramammary node) and less often as
masses with calcifications (27, or 18%, including one
asymmetry with calcifications) or isolated clusters of cal-
cifications (11, or 7%). Seventeen lesions (11%) were not
visible on MX alone, even retrospectively. Ultrasound
still images (’screen saves’) were available for 90 patients
(82%); for the remaining 20 (18%), no lesions were seen
on US and therefore no still images were obtained. Only
one mild adverse reaction to the administration of iodi-
nated contrast agent - a limited urticaria that did not
require specific treatment - was observed. The patient
was observed for 20 minutes to ensure clinical stability
and recovery.
Area under the ROC curve increased for each reader
with the addition of CEDM (Table 2 and Figure 2).
Overall multireader areas under the ROC curve were
0.827 (standard error (SE) = 0.036) for MX ± US and
0.871 (SE = 0.027) for MX ± US ± CEDM. The average
increase in ROC area, 0.043 (SE = 0.019), was statisti-
cally significant (P = 0.045). When BI-RADS score of 4
Figure 8 Invasive lobular carcinoma in a 67-year-old woman
with left nipple stiffness and retraction. The iodine-enhanced,
contrast-enhanced digital mammography, mediolateral oblique
images clearly depicts non-mass regional enhancement in the
inferior quadrant.
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or 5 was used to define a positive test, per-patient sensi-
tivity increased slightly for three of six study readers
and decreased slightly for the other three; the average
change was -0.003: SE = 0.022, P = 0.910 not significant
(NS) (Table 3) (Figures 3, 4, 5, 6, 7, 8, 9). Specificity
increased for five of six study readers and decreased for
the sixth; the average change was 0.040: SE = 0.040, P =
0.336 NS (Table 3). Similar results were obtained using
the 7-point probability of malignancy scale.
The addition of CEDM to MX and US enabled radiol-
ogists to find additional malignant lesions (Table 4)
Figure 9 Invasive lobular carcinoma in a 67-year-old woman with left nipple stiffness and retraction. The contrast-enhanced transaxial
breast magnetic resonance image shows the same non-mass regional enhancement than CEDM images.
Table 4 Per-lesion sensitivity to malignant lesions and
false-positive marks per case using BI-RADS score of at
least 4 to define a positive mark
Reader MX ± US MX ± US ± CEDM Difference P value
Sensitivity
1 0.702 ± 0.050 0.762 ± 0.047 0.060 0.13
2 0.738 ± 0.048 0.81 ± 0.043 0.071 0.08
3 0.738 ± 0.048 0.845 ± 0.040 0.107 0.01
4 0.762 ± 0.047 0.821 ± 0.042 0.060 0.07
5 0.702 ± 0.05 0.738 ± 0.048 0.036 0.50
6 0.631 ± 0.053 0.690 ± 0.051 0.060 0.18
Overall 0.712 ± 0.043 0.778 ± 0.040 0.065 ± 0.024 0.006
95% CI 0.628 to 0.797 0.697 to 0.858 0.019 to 0.112
False-positive marks per case (cases without malignant lesions)
1 0.478 ± 0.056 0.652 ± 0.064 0.174 0.034
2 0.565 ± 0.056 0.435 ± 0.052 -0.130 0.128
3 0.652 ± 0.058 0.674 ± 0.067 0.022 0.745
4 1.043 ± 0.06 0.978 ± 0.065 -0.065 0.545
5 0.717 ± 0.052 0.609 ± 0.051 -0.108 0.134
6 0.478 ± 0.056 0.478 ± 0.063 0.000 1.000
Overall 0.656 ± 0.092 0.638 ± 0.089 -0.018 ± 0.050 0.726
95% CI 0.443 to 0.869 0.434 to 0.842 -0.135 to 0.099
BI-RADS, Breast Imaging, Reporting and Data System; CEDM, contrast-
enhanced digital mammography; CI, confidence interval; MX, mammography;
US, ultrasonography.
Figure 10 Multifocal invasive ductal carcinoma in a 53-year-old
woman with dense breasts. The right craniocaudal view
mammogram shows a very dense breast with an uncertain opacity
in the inner quadrant (arrows).
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(Figures 10, 11, 12, 13, 14, 15, 16). Overall sensitivities
were 0.712 (SE = 0.043) for MX ± US and 0.778 (SE =
0.040) for MX ± US ± CEDM. The increase in sensitiv-
ity of 0.065 (SE = 0.024) was statistically significant (P =
0.006). In patients without malignant lesions, the aver-
age number of reader findings with a BI-RADS score of
4 or 5 decreased for three of six study readers, did not
change for one, and increased for two readers with the
addition of CEDM (Figures 17, 18, 19, 20, 21, 22). Over-
all, there was a slight decrease in false-positive marks
per case with the addition of CEDM, from 0.656 using
MX ± US to 0.638 using MX ± US ± CEDM; this
decrease was not statistically significant (-0.018 ± 0.050,
P = 0.726 NS). Similar results were obtained by using
the 7-point probability of malignancy scale.
Feature visibility for MX ± CEDM was rated as similar
to MX ± US in 43.3% of study readings, slightly better
in 21.2%, and better in 15.9% (Table 5). Overall, feature
visibility on MX ± CEDM was rated similar to or better
than feature visibility on MX ± US in 80.5% of ratings
(95% CI 74.5% to 86.5%).
Discussion
Contrast-enhanced digital MX is a new breast imaging
technique that aims at demonstrating breast carcinoma
angiogenesis. Technical and clinical experience has been
acquired and encouraging results have been published
during the last few years on CEDM as an adjunct to
MX [12-15]. Temporal subtraction was first tested with
an approach similar to that of breast MRI [12-14].
These studies have shown the capability of CEDM to
depict tumor angiogenesis in invasive breast cancer and
have demonstrated contrast uptake in most malignant
lesions. The main advantage of temporal subtraction is
its ability to analyze the kinetics of time-enhancement
Figure 11 Multifocal invasive ductal carcinoma in a 53-year-old
woman with dense breasts. The left craniocaudal view
mammogram shows a very dense breast with no obvious lesion. Figure 12 Multifocal invasive ductal carcinoma in a 53-year-old
woman with dense breasts. The right mediolateral oblique view
mammogram shows a very dense breast with an uncertain opacity
in the inferior quadrant (arrows).
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curves. Kinetic curve assessment using CEDM, however,
has failed to demonstrate clinical relevance [12-14].
Both benign and malignant breast tumors, evaluated by
using a temporal CEDM technique, have shown progres-
sive enhancement. Moreover, poor correlation was
observed between the intra-tumoral mean vascular
Figure 13 Multifocal invasive ductal carcinoma in a 53-year-old woman with dense breasts . The left mediolateral oblique view
mammogram shows a very dense breast with no obvious lesion.
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density evaluated on CD34-immunostained histological
sections and quantitative characteristics of time-
enhancement kinetics [14]. One hypothesis to explain
this lack of washout in most cancers depicted with
CEDM is that, unlike MRI, CEDM is a two-dimensional
projection imaging technique and region-of-interest eva-
luations are made in a column of breast tissue that is
the summation of enhancing tumor and enhancing sur-
rounding normal breast parenchyma.
In this study, CEDM examinations were performed by
using a dual-energy technique. Only one preliminary
clinical study using the dual-energy technique has been
published. Lewin and colleagues [11] examined 26
women (14 with malignant lesions and 12 with benign
lesions) scheduled for breast biopsy with a pre- and
post-contrast MLO acquisition. Twelve of the 13 inva-
sive carcinomas (92%) demonstrated strong or moderate
enhancement, and one demonstrated weak enhance-
ment. Five of these invasive cancers were not detected
on conventional MX. Of the 12 benign lesions, 10 (83%)
demonstrated no enhancement and two demonstrated
weak enhancement on CEDM images. The study exami-
nation by Lewin and colleagues included low- and high-
energy exposures during a single breast compression in
the MLO projection. The breast was then released from
compression, and contrast agent was administered. After
a delay of about 150 seconds, the breast was compressed
again, and low- and high-energy exposures were
repeated. From these images, pre- and post-contrast
dual-energy images were created. High-energy images
were acquired at 44 kVp with an 8-mm aluminum filter,
and most low-energy images were acquired at 30 kVp
with an Mo target-Mo filter combination or at 33 kVp
with an Rh target-Rh filter combination.
The experimental setup that was used in our study has
been significantly improved in comparison with the pio-
neering work of Lewin and colleagues. In our exams, the
contrast agent was first administered to the patient two
minutes before starting breast compression and image
acquisition. Most low-energy images were acquired with
an Rh target-Rh filter combination. Techniques for high-
energy exposures were optimized to deliver the highest
contrast-to-noise ratio for the lowest x-ray dose delivered
to the patient [32]. Overall, those optimized parameters
achieved similar contrast-to-noise ratios of iodine uptake
in comparison with the acquisition parameters reported
Figure 14 Multifocal invasive ductal carcinoma in a 53-year-old
woman with dense breasts. The ultrasound image clearly
demonstrates a 26-mm hypoechoic mass with irregular margins
highly suggestive of malignancy.
Figure 15 Multifocal invasive ductal carcinoma in a 53-year-old
woman with dense breasts. The iodine-enhanced, contrast-
enhanced digital mammography, right craniocaudal image readily
depicts the main mass (arrow) and three additional adjacent
nodules (arrowheads).
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by Lewin and colleagues, but with a breast dose that is
reduced by a factor of 2 (breast was 5 cm thick, 50%
glandular). Moreover, optimized acquisition parameters
yield high- and low-energy images that enable better tex-
ture cancellation when image recombination was applied
[17].
More recently, we published the results of an initial
single-reader evaluation of dual-energy CEDM in the
same patient population as this study [15]. The purpose
of that investigational study was to evaluate the clinical
value of CEDM versus MX ± US. Encouraging results
prompted the new study reported in this article, which
involved six independent readers who evaluated CEDM,
not compared with MX ± US but as an adjunct to MX
± US in diagnostic work-up, in order to reflect more
accurately a potential routine clinical use of this
technique. We performed a multireader review (six
readers) of all images with per-reader and across-reader
analyses. The addition of CEDM to MX ± US increased
the ability of radiologists to discriminate between
patients with malignant lesions and those without them.
All individual readers improved their performance, and
the area under ROC curves averaged across readers was
significantly higher for MX ± US ± CEDM than for MX
± US. Moreover, the addition of CEDM to MX allowed
the detection of more breast lesions with higher per-
lesion sensitivity than MX ± US alone for all six readers,
and the average breast cancer sensitivity based on BI-
RADS score increased significantly from 71% to 78%
without an increase in false positives. Indeed, CEDM
imaging may help improve the visibility of suspicious
findings and their differentiation thanks to its depiction
of tumor angiogenesis. CEDM has the potential to
Figure 16 Multifocal invasive ductal carcinoma in a 53-year-old
woman with dense breasts. The iodine-enhanced, contrast-
enhanced digital mammography, right mediolateral oblique image
readily depict the main mass (arrow) and three additional adjacent
nodules (arrowheads).
Figure 17 Histologically proven normal breast parenchyma in
a 69-year-old woman. The right craniocaudal view mammogram
shows an opacity with irregular margins (arrow).
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increase breast cancer detection rates, improve staging
of breast cancers, and improve patient selection for
biopsy.
We chose to assess the adjunct of CEDM to MX ± US
rather than MX alone because MX ± US corresponds to
current clinical practice in the diagnostic setting. It
could be useful, however, to perform CEDM before US
because CEDM allows more accurate localization of the
lesion than MX alone and provides better guidance for
additional or second-look breast US. Moreover, in quali-
tative and subjective analysis using a Likert scale,
CEDM was considered by radiologists to allow a clearer
depiction of breast lesions. Indeed, the visibility of
lesions with the addition of CEDM to MX was consid-
ered to be superior to MX ± US in more than 40% of
cases, although some readers had little or no experience
in interpreting CEDM images. These results highlight
the contribution of contrast media injection in the
depiction of breast cancers. CEDM adds functional
information complementary to the morphologic findings
of MX, aiding the detection and characterization of
breast lesions.
The use of iodinated contrast agents, however, is not
completely devoid of risk. Most adverse side effects are
minor and have decreased considerably with the use of
low-osmolality contrast media. Still, life-threatening
reactions, though rare, can occur in the absence of any
specific risk factors and with any type of contrast media
[33]. All personnel (nurses, technologists, and radiolo-
gists) who administer contrast media must be fully pre-
pared to treat even the most severe reaction, and
adequate equipment and supplies must be available in
the MX suite.
Figure 18 Histologically proven normal breast parenchyma in
a 69-year-old woman. The left craniocaudal view mammogram is
normal.
Figure 19 Histologically proven normal breast parenchyma in
a 69-year-old woman. The right mediolateral oblique view
mammogram shows an opacity with irregular margins (arrow). This
lesion is classified as a BI-RADS (Breast Imaging, Reporting and Data
System) score of 4.
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In our study, CEDM exams were performed on
women recalled for work-up of findings unresolved after
MX and US. CEDM was used as a problem-solving tool
similarly to additional special MX views. Two-view (CC
and MLO) dual-energy CEDM examinations were per-
formed only on the suspicious breast. However, unlike
the temporal subtraction technique, dual-energy CEDM
has the potential to enable bilateral examinations with
only one contrast agent injection and may be more con-
venient for staging newly diagnosed breast cancers.
Dual-energy CEDM also allows shorter acquisition dura-
tion than temporal subtraction techniques and does not
require extended breast compression. This could result
in better acceptance from patients and fewer technical
problems, such as misregistration of subtracted images.
In dual-energy CEDM, contrast is injected without
breast compression, thus avoiding patient motion linked
to the heat sensation caused by the arrival of contrast
agent and minimizing the impact of compression on
contrast agent uptake in the breast.
Conclusions
Dual-energy CEDM is a new and advanced clinical
application of FFDM and is easily implemented, fast,
and reproducible, and breast doses are comparable to
those of standard digital MX. Dual-energy contrast-
enhanced digital MX as an adjunct to MX ± US
improves the diagnostic accuracy and the per-lesion sen-
sitivity to malignant breast lesions of all readers in com-
parison with MX ± US alone and allows similar or
improved visibility of breast lesions in most cases.
CEDM may be a useful adjunct to diagnostic MX and a
promising problem-solving and staging tool and may
provide a cost-effective alternative to breast MRI for
some clinical indications. Further research to evaluate
Figure 20 Histologically proven normal breast parenchyma in
a 69-year-old woman. The left mediolateral oblique view
mammogram is normal.
Figure 21 Histologically proven normal breast parenchyma in
a 69-year-old woman. The iodine-enhanced, contrast-enhanced
digital mammography, right craniocaudal image clearly
demonstrates no obvious contrast uptake in the area of the nodule
depicted on mammography.
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the diagnostic accuracy and cost-effectiveness of CEDM
compared with MRI is needed to define the appropriate
role of CEDM in the future.
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